8-K/A: OSR Holdings Completes Merger with Bellevue Life Sciences Acquisition Corp, Files Amended 8-K

OSR Holdings files an amendment to its previous 8-K report to include audited financial statements, management's discussion and analysis, and unaudited pro forma financial information following its merger with Bellevue Life Sciences Acquisition Corp.

Summary

• OSR Holdings, Inc. filed an amendment to its previous 8-K report on February 14, 2025.
• The amendment includes audited financial statements for OSR Holdings Co., Ltd. for the years ended December 31, 2024 and 2023.
• It also includes management's discussion and analysis of financial conditions and results of operations for the same periods.
• Additionally, the amendment contains unaudited pro forma condensed combined financial statements as of December 31, 2024, and for the years ended December 31, 2023 and 2024.
• The company completed a business combination with Bellevue Life Sciences Acquisition Corp. (BLAC) on February 14, 2025, with BLAC merging into OSR Holdings.
• Following the merger, BLAC changed its name to OSR Holdings, Inc. and began trading its common stock and warrants on the Nasdaq Stock Market LLC under the symbols OSRH and OSRHW, respectively, starting February 18, 2025.
• The merger is accounted for as a reverse recapitalization, with OSR Holdings considered the accounting acquirer.
• Net sales increased by KRW 362 million, or 8%, reflecting an increase in net sales for RMC, due primarily to expansion its of sales product portfolio.
• Cost of sales increased by KRW 430 million, or 13%, mainly due to the increase in import volumes for RMC, which purchases products from global manufacturers for domestic distribution (hence the increase in cost of sales).
• Gross profit decreased by approximately KRW 70 million, or 6%.
• SG&A expenses increased by 7% in 2024, primarily from the amortization of acquired patents, which increased by KRW 983 million, or 8%, due to increased amortization of Darnatein patents, with deemed acquisition date of March 31,2023, and commissions and professional fees which increased by KRW 855 million, or 116%, due to costs related to business combination activities.
• Loss before income taxes for the year ended December 31, 2024 increased by KRW 484 million, or 3.1%, from a loss of KRW 15.7 billion in 2023 to KRW 16.2 billion in 2024, reflecting higher SG&A expenses, and, to a lesser extent, reduced gross profits from operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's revenue growth, increasing losses and the need for capital raising temper the positive aspects. The future outlook suggests continued challenges.

Positives

• Net sales increased by 8% in 2024, indicating revenue growth.
• Interest income increased from KRW 23 million in 2023 to KRW 29 million in 2024, an increase of 29%.
• Interest expense decreased by KRW 384 million, or 85%, from KRW 454 million in 2023 to KRW 70 million in 2024, despite an increase in short-term and long-term financial liabilities by KRW 2,145 million and KRW 271 million, respectively, in 2024.
• The Health Insurance Review and Assessment Service of Korea (HIRA) will officially increase the reimbursement amount by 2% from April 1, 2025, which is expected to partially offset the impact of unfavorable KRW exchange rates.

Negatives

• Gross profit decreased by approximately KRW 70 million, or 6%.
• Gross margin percentage decreased from 26.4% to 23.0%, primarily due to KRW depreciation that led to higher costs of imported goods for RMC.
• Loss before income taxes increased by 3.1% to KRW 16.2 billion in 2024.
• OSR Holdings has incurred significant operating losses and negative cash flows from its operations.
• OSR Holdings expects revenue to decrease in 2025 and possibly longer until RMC can replace the sales of Penumbras products by increasing other sales or securing additional products from other manufacturers.

Risks

• The company has a history of operating losses and negative cash flows.
• The termination of RMC's contract with Penumbra could lead to decreased revenue in 2025 and beyond.
• Currency depreciation (KRW) negatively impacts gross margins due to higher costs of imported goods.
• The company needs to raise capital to fund operations.

Future Outlook

OSR Holdings expects revenue to decrease in 2025 until RMC can replace the sales of Penumbras products. The company also anticipates increased R&D expenses and SG&A expenses associated with operating as a public company.

Industry Context

The document reflects a life sciences company navigating the challenges of revenue growth, cost management, and the transition to being a publicly traded entity. The focus on oncology and immunology aligns with high-growth areas in the healthcare industry.

Comparison to Industry Standards

• It is difficult to compare OSR Holdings directly to industry standards without knowing the specific sub-sectors in which its subsidiaries operate (e.g., medical device distribution, drug development).
• However, the document provides some context for comparison.
• For example, the gross margin percentage of 23.0% in 2024 can be compared to gross margins of medical device distributors or pharmaceutical companies.
• Similarly, the R&D expenses as a percentage of revenue can be compared to industry benchmarks for biotech companies.
• The document mentions VAXIMM and Darnatein as bioplatform companies, which suggests a business model similar to companies like Moderna or BioNTech, although these are much larger and more mature companies.
• The hub-and-spoke business model of OSR Holdings is similar to other holding companies in the life sciences industry, such as Danaher or Thermo Fisher Scientific, which acquire and integrate smaller companies with innovative technologies.

Related Party Transactions

• The Group has a loan agreement with Bellevue Capital Management Europe AG and as of December 31, 2024, the outstanding balance was 882,000,000 (3.00% interest rate at December 31, 2024), which matures in March 2025.
• The Group has a loan agreement with Bellevue Capital Management Europe AG and as of December 31, 2024, the outstanding balance was 382,200,000 (3.00% interest rate at December 31, 2024), which matures in July 2025.
• The Group has a loan agreement with Bellevue Life Sciences Acquisition Corp. and as of December 31, 2024, the outstanding balance was 441,000,000 (3.96% interest rate at December 31, 2024), which matures in October 2025.
• The Group has a loan agreement with an individual and as of December 31, 2024, the outstanding balance was 73,500,000 (7.00% interest rate at December 31, 2024), which matures in December 2025.
• The Group has multiple loan agreements with an individual and as of December 31, 2024, the outstanding balance was 600,000,000 (0% interest rate at December 31, 2024), which mature various dates in 2025.
• The Group has a loan agreement with an individual and as of December 31, 2023, the outstanding balance was 300,000,000 (0% interest rate at December 31, 2023), 33,000,000 of which was paid in 2024.
• The remaining balance of 267,000,000 (0% interest rate at December 31, 2024) was outstanding as of December 31, 2024, which matures in December 2025.
• The Group has a loan agreement with an individual and as of December 31, 2023, the outstanding balance was 200,000,000 (0% interest rate at December 31, 2023), which was fully paid in 2024.

Stakeholder Impact

• Shareholders: The merger and Nasdaq listing provide potential for increased visibility and liquidity, but the company's financial performance and future outlook may cause concern.
• Employees: The merger and restructuring could lead to uncertainty, but also potential opportunities for growth and development.
• Customers: The company's focus on innovation and new therapies could benefit customers in the long term.
• Creditors: The company's debt levels and need for capital raising may increase risk for creditors.

Next Steps

• RMC needs to replace the sales of Penumbras products by increasing other sales or securing additional products from other manufacturers.
• The company will continue to execute its business plan to further expand its business by discovering and investing in innovative healthcare companies with cutting-edge technology and creating operating synergies between subsidiaries.

Key Dates

Keywords

merger, financial statements, OSR Holdings, Bellevue Life Sciences Acquisition Corp, reverse recapitalization, audited, unaudited, Nasdaq, financial results